Company profile: Luminist Labs
1.1 - Company Overview
Company description
- Provider of a rapidly scalable, low-cost diagnostic platform for early detection and diagnosis of liver disease and screening for many diseases.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Luminist Labs
Ultimovacs
HQ: Norway
Website
- Description: Provider of novel immunotherapies against cancer, including UV1, a peptide-based therapeutic cancer vaccine inducing a specific T cell response against the universal cancer antigen telomerase. Offers TET vaccine adjuvant technology targeting antigen-presenting cells, and conducts clinical trials (INITIUM, NIPU, DOVACC, FOCUS) evaluating UV1 with checkpoint inhibitors across melanoma, mesothelioma, ovarian, and head and neck cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ultimovacs company profile →
Janux Therapeutics
HQ: United States
Website
- Description: Provider of immunotherapies that activate T cells in the tumor microenvironment while sparing healthy tissue, including PSMA-TRACTr (JANX007) for metastatic castration-resistant prostate cancer and EGFR-TRACTr (JANX008) in Phase 1 for carcinomas, built on proprietary TRACTr and TRACIr bispecific platforms; partnered with Merck to develop next-generation T cell engager immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Janux Therapeutics company profile →
Onxeo
HQ: France
Website
- Description: Provider of oncology drug R&D and platforms, offering Beleodaq (belinostat), a histone deacetylase inhibitor marketed in the US for injection; Livatag, a nanoparticle doxorubicin in Phase III for primary liver cancer; and pipeline programs including platON, a decoy oligonucleotide platform for cancer and inflammatory diseases; AsiDNA, a DNA-repair decoy; and VIO-01, a pan‑DDR decoy activating STING.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onxeo company profile →
Complix
HQ: Belgium
Website
- Description: Provider of Alphabody biopharmaceuticals focused on discovering and developing a novel class of therapeutics that bind with high affinity to disease targets. Offerings include Cell Penetrating Alphabodies to modulate intracellular protein interactions, a pipeline for intracellular targets in cancer, autoimmunity, and viral diseases, and anti-Covid-19 Alphabodies targeting SARS-CoV-2 fusion for prophylactic and therapeutic use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Complix company profile →
Intact Medical
HQ: United States
Website
- Description: Provider of minimally invasive systems for volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intact Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Luminist Labs
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Luminist Labs
2.2 - Growth funds investing in similar companies to Luminist Labs
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Luminist Labs
4.2 - Public trading comparable groups for Luminist Labs
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →